A PHASE 1 OPEN-LABEL STUDY OF KPT-9274 IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
Primary Objective
This study will evaluate the safety and tolerability of oral KPT-9274 for the treatment of patients with relapsed or refractory acute myeloid leukemia
Details
Age
Adult
Type of Study
Treatment
Locations
Lone Tree Medical Center
University of Colorado Hospital
Principal Investigator
Daniel Pollyea, MD, MS
Study ID
Protocol Number: 20-2350
More information available at ClinicalTrials.gov: NCT04914845
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers